Akèy › Kansè poumon › Virginia › Arlington
Etid klinik pou Kansè poumon nan Arlington, VA
41 etid pou Kansè poumon ap chèche patisipan nan sit nan ak bò kote Arlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Ap rekriteFaz 2
- Virginia Cancer Specialists (VCS) ( Site 0408), Fairfax · 11 mi lwen
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Fairfax · 11 mi lwen
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Ap rekriteFaz 1
- Inova Schar Cancer Infusion Pharmacy, Fairfax · 11 mi lwen
- Inova Schar Cancer, Fairfax · 11 mi lwen
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Research Site, Fairfax · 11 mi lwen
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Next Oncology Virginia Cancer Specialist, Fairfax · 11 mi lwen
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Ap rekriteFaz 1
- NEXT - Virginia, Fairfax · 11 mi lwen
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Ap rekriteFaz 1
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- USO - Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi lwen
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi lwen
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Oncology, Fairfax · 11 mi lwen
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Ap rekriteFaz 3
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Inova Schar Cancer Institute, Fairfax · 11 mi lwen
- Inova Fair Oaks Hospital, Fairfax · 11 mi lwen
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi lwen
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Fairfax · 11 mi lwen
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- NEXT Oncology Virginia, Fairfax · 11 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Next Oncology Virginia, Fairfax · 11 mi lwen
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Ap rekriteFaz 1/2
- NEXT Oncology, Fairfax · 11 mi lwen
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi lwen
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Ap rekriteFaz 2
- Inova Fairfax Hospital, Fairfax · 11 mi lwen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- NEXT Virginia, Fairfax · 11 mi lwen
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- NEXT Virginia, Fairfax · 11 mi lwen
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi lwen
Etid Kansè poumon nan lòt vil
- Houston, TX78 etid
- Boston, MA62 etid
- New York City, NY60 etid
- Los Angeles, CA45 etid
- Washington, DC41 etid
- Chicago, IL41 etid
- Nashville, TN40 etid
- Baltimore, MD40 etid
- St. Louis, MO39 etid
- Columbus, OH37 etid
- Philadelphia, PA36 etid
- Seattle, WA33 etid
Lòt etid nan Arlington
- Kansè Poumon ki pa ti selil104 etid
- Kansè Metastatik53 etid
- Kansè kolorektal52 etid
- Kansè (tout kalite)48 etid
- Kansè nan tete46 etid
- Kansè ovè46 etid
- Kansè Endomèt39 etid
- Kansè pankreyas33 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
- Kansè poumon selil ti23 etid
- Kansè tete negatif triple20 etid
- Kansè lestomak20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.